Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Clinical oncology 2024-03, Vol.21 (3), p.171-172
Hauptverfasser:	Berton Giachetti, Pier Paolo M., Curigliano, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2779/777 692/699/67/1059/602 692/699/67/1347 692/700/565/1436/1437 692/700/565/1436/2185 Acrylamides - therapeutic use Aminoquinolines Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer therapies Chemotherapy Councils Docetaxel - therapeutic use ErbB-2 protein Female Humans Medicine Medicine & Public Health Metastases Metastasis News & Views news-and-views Oncology Receptor, ErbB-2 - genetics Standard of care Toxicity Trastuzumab Trastuzumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.
ISSN:	1759-4774 1759-4782 1759-4782
DOI:	10.1038/s41571-023-00854-y